Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anamaris Torres-Sanchez
Observed name:
A. Torres-Sanchez
Institutions:
University of Puerto Rico, Medical Sciences Campus,
University of Puerto Rico System
Observed institutions:
University of Puerto Rico, Medical Sciences Campus,
University of Puerto Rico at Río Piedras,
University of Puerto Rico System,
San Juan Bautista School of Medicine
ORCID:
0000-0002-5726-255X
Observed ORCID:
0000-0002-5726-255X
OpenAlex ID:
A5008089125
Unraveling the Impact of Six Pentacyclic Triterpenes Regulating Metabolic Pathways on Lung Carcinoma Cells
2024
·
Anamaris Torres-Sanchez
, Grace Torres
, et al.
·
Pharmaceuticals
·
18
PDF
Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models
2023
·
Anamaris Torres-Sanchez
, Michael Rivera-Robles
, et al.
·
Frontiers in Oncology
·
12
Deferasirox’s Anti-Chemoresistance and Anti-Metastatic Effect on Non-Small Cell Lung Carcinoma
2024
·
Yamixa Delgado
, Anamaris Torres-Sanchez
, et al.
·
Biomedicines
·
8
PDF
Post-Hurricane Distress Scale (PHDS): Determination of General and Disorder-Specific Cutoff Scores
2022
·
Yonatan Carl
, Andy Vega
, et al.
·
International Journal of Environmental Research and Public Health
·
4
PDF
M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
2026
·
Nilmary Grafals-Ruiz
, Julia I. Medina
, et al.
·
Molecular Cancer Therapeutics
·
2
PDF
Data from M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
2026
·
Nilmary Grafals-Ruiz
, Julia I. Medina
, et al.
·
1
Supplementary Table 1 from M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
2026
·
Nilmary Grafals-Ruiz
, Julia I. Medina
, et al.
Supplementary Figure S5 from M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
2026
·
Nilmary Grafals-Ruiz
, Julia I. Medina
, et al.
Supplementary Figure S3 from M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
2026
·
Nilmary Grafals-Ruiz
, Julia I. Medina
, et al.
Supplementary Figure S4 from M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
2026
·
Nilmary Grafals-Ruiz
, Julia I. Medina
, et al.
Supplementary Figure S1 from M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
2026
·
Nilmary Grafals-Ruiz
, Julia I. Medina
, et al.
Supplementary Figure S2 from M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
2026
·
Nilmary Grafals-Ruiz
, Julia I. Medina
, et al.
Supplementary Table 2 from M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
2026
·
Nilmary Grafals-Ruiz
, Julia I. Medina
, et al.
Abstract 4525: Potential of Rac and Cdc42 inhibitors as pancreatic cancer therapeutics.
2026
·
Anamaris Torres-Sanchez
, Ailed Cruz-Collazo
, et al.
·
Cancer Research
Abstract 7099: Novel Ect2-Rac inhibitor CPV-337 in breast and pancreatic cancer
2026
·
Jessica Colon Gonzalez
, Nilmary Grafals-Ruiz
, et al.
·
Cancer Research
Abstract PS1-11-12: Rac/cdc42 inhibitor MBQ-167 in the estrogen receptor positive breast cancer tumor microenvironment
2026
·
A. Cruz Collazo
, N. Zaragoza-Rodriguez
, et al.
·
Clinical Cancer Research
Abstract PS3-12-08: Rac/cdc42 inhibitor mbq-167 modulates the breast tumor immune microenvironment
2026
·
A. Torres-Sanchez
, A. Cruz-Collazo
, et al.
·
Clinical Cancer Research
Rac/Cdc42 inhibitors target pancreatic cancer cells and macrophages in the tumor microenvironment
2026
·
Anamaris Torres-Sanchez
, Stephanie Dorta-Estremera
, et al.
·
Cancer Treatment and Research Communications
Abstract P1-07-18: Testing the Rac/Cdc42 inhibitor MBQ-167 in ex vivo cultures of Hispanic TNBC tissue
2025
·
Anamaris Torres-Sanchez
, Nilmary Grafals-Ruiz
, et al.
·
Clinical Cancer Research
Abstract 7628: Pharmacodynamic biomarkers for Rac and Cdc42 inhibitor efficacy
2024
·
Anamaris Torres-Sanchez
, Ailed M. Cruz-Collazo
, et al.
·
Cancer Research
Abstract A007: Expression and activity of Rac, Cdc42, and their downstream effector PAK in Puerto Rican pancreatic cancer patients
2024
·
Anamaris Torres-Sanchez
, Jahdiel Berrios-Rodriguez
, et al.
·
Cancer Research
Abstract 1586: The potential therapeutic effect of the Rac/Cdc42 inhibitor MBQ-167 in glioblastomain vitro
2023
·
Derealise Garcia Almedina
, Nilmary Grafals-Ruiz
, et al.
·
Cancer Research
Abstract 2483: Rac and Cdc42 Inhibitors in Rheumatoid Arthritis Therapy
2023
·
Luis Borrero Garcia
, Anamaris Torres-Sanchez
, et al.
·
Journal of Biological Chemistry
Show more works
View as search
Works count:
23
Citation count:
45
H-index:
4
I10-index:
2
Year
Topic
Type